Concert Pharmaceuticals, Inc. (CNCE)

CNCE was delisted on the 3rd of March, 2023.

• Market cap: $402M

About: Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Employees: 64